Results 61 to 70 of about 50,442 (246)
Background Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin’s lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and Liso-cel)
Manel Juan +13 more
doaj +1 more source
Background Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Programmed cell death 1 ligand 1) axis
Ang Zhang +17 more
doaj +1 more source
Single‐cell profiling across bone marrow, spleen, mesenteric lymph, and blood in rhesus monkeys reveals organ Immunosenescence. GZMB rises with age, particularly in cytotoxic and terminally exhausted CD8+ T cells, and BHLHE40 emerges as a key transcription factor enriched across multiple CD8+ subsets, regulating pro‐inflammatory and exhaustion‐related ...
Shengnan Wang +10 more
wiley +1 more source
This study presents a vascularized 3D tumor model to investigate immune–stromal–tumor interactions under allogeneic PBMC perfusion. While immune cells induced tumor shrinkage, they also promoted vascular regression, stromal activation, and cancer cell invasion.
Alexandra Raab +8 more
wiley +1 more source
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu +18 more
wiley +1 more source
cDC1 Subtype‐Specific In Vivo Targeting of Liposomes
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf +11 more
wiley +1 more source
Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL).
Pablo Domizi +25 more
doaj +1 more source
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou +9 more
wiley +1 more source

